Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail
30 Duke Medicine Circle, 25177 Morris Bldg, Durham, NC 27710
Education and Training
- Hematology/Oncology, The University of Chicago, 2007 - 2010
- Internal Medicine, The University of Chicago, 2004 - 2007
- M.D., University of North Carolina - Chapel Hill, 2004
Grants
- IDE196 in Metastatic Uveal or Non-Uveal Melanoma with GNAQ/11 Mutations or PRKC Fusions (IDEAYA)
- A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
- Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
- An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
- A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
- A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
- A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
- A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
- A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
- A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)
- BMS Rollover (CA2098TT)
- Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
- A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
- A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melan
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma